Duplication, Interactions and Contraindications

Introduction

A prescription can be correct on its own and still cause a problem next to something else the patient uses. A second product may contain the same ingredient. A second medicine may be ordered for the same purpose. A supplement, food, health condition or lab test may change what a medicine does, or what a result means.

As a pharmacy technician, you will often be the first person to notice these overlaps. You may see them on a screen, on a label or in something the patient says. Your job is to recognize the overlap and gather the facts. The pharmacist's job is to decide what it means for this patient.

After this lesson, you should be able to:

• Tell a duplicate ingredient, a therapeutic duplication and an interaction apart, and say which question each one answers.
• Explain how a contraindication differs from a general caution, using label wording as evidence.
• List the facts a pharmacist needs to review a flagged combination, and put them in a clear handoff.
• Avoid adding claims a source does not make, such as the direction of an interaction or proof that a drug caused a symptom.

Before you start: You need only everyday reading and simple addition. Every pharmacy term is defined when it first appears. If you want more practice separating a medicine's ingredient from its name, see Read a medicine identity before learning a name.

Three Different Questions

Each of these three terms answers a different question about the same patient's medicines:

• Duplicate ingredient asks: Is the same active ingredient coming from more than one product?
• Therapeutic duplication asks: Are two or more medicines ordered for the same purpose?
• Interaction asks: Does something else change how this medicine acts, or what its test results mean?

Two terms come first:

• An active ingredient is the substance in a product that does the medical work. Names on the box can differ while the active ingredient is the same.
• An indication is the reason a medicine is used, such as high blood pressure or nausea.

One patient's profile can raise all three questions at once. They are not competing labels where you must pick one. Each question checks something different.

Duplicate Ingredients: Read Ingredients, Not Names

Plain-English takeaway: The same active ingredient can reach the patient from two products with different names. The body receives the total, whatever the boxes are called.

The FDA reminds consumers that different over-the-counter (OTC) products can contain the same active ingredient. People taking more than one should check the active ingredients so they don't take too much of one. OTC labels list each active ingredient's name and amount in the "Active Ingredients" section. That section is where you check, not the brand name on the front.

Worked example: adding the same ingredient from two products

Fictional case. Every number is supplied here. This is not dosing advice.

A customer brings two OTC products to the counter and says they plan to take one dose of each at bedtime.

• Product A's label: acetaminophen 325 mg per caplet; dose is 2 caplets.
• Product B's label: acetaminophen 500 mg per tablet; dose is 2 tablets.

Step 1: Find the shared ingredient. Both list acetaminophen. The products have different names and purposes, but the ingredient matches.

Step 2: Work out the amount from each product. A: 2 × 325 mg = 650 mg. B: 2 × 500 mg = 1,000 mg.

Step 3: Add them. 650 mg + 1,000 mg = 1,650 mg of acetaminophen at one time.

Step 4: Check the size of the answer. The total must be larger than either product alone, and it is.

Step 5: Hand it off. Tell the pharmacist both products, the amounts and the planned timing.

Correct arithmetic produces a fact, not a decision. This lesson gives no safe limit, and the total alone does not tell you whether the plan is acceptable. Deciding that, and recommending an OTC product, belongs to the pharmacist.

Changed case: different ingredients, same purpose

Now suppose Product B contained ibuprofen instead of acetaminophen. No ingredient appears twice, so this is not a duplicate ingredient.

Both products may still be taken for pain. That raises a different question, the same purpose question, which the next section covers. When one fact changed, the label changed. That is why it pays to ask which question you are answering.

Combination products hide duplicates

Some products contain more than one active ingredient. MedlinePlus lists Zestoretic as a brand containing lisinopril and hydrochlorothiazide. Suppose a profile shows that product and also plain lisinopril. Lisinopril is then arriving twice, even though neither name repeats the other. (A brand listed in a reference shows what that name has been associated with. It does not show what is currently sold.)

MedlinePlus also gives a direct example for warfarin, a medicine that reduces blood clotting. It tells patients not to take two or more medications that contain warfarin at the same time. It also tells them to check with a doctor or pharmacist if they are unsure whether a product contains warfarin.

Same ingredient does not mean same product

Lisinopril comes as a tablet and as a liquid taken by mouth. The ingredient is the same, but the dosage form and how a dose is measured differ. A shared ingredient tells you to check for duplication. It does not make two products interchangeable.

Question 1

A profile shows a customer's prescription for warfarin. They also mention that a family member gave them some "blood thinner pills" from a different bottle, and they aren't sure what is in them. Which of the three questions does this raise first, and what should you do?

Therapeutic Duplication: Same Purpose, Unclear Intent

Plain-English takeaway: Two or more medicines are ordered for the same reason. That might be a mistake, or it might be planned. Someone has to find out which.

The Joint Commission, which accredits hospitals and other care organizations, describes therapeutic duplication as more than one medication ordered for the same indication. It says this can be acceptable. It also says the orders must make clear which of three situations applies:

1. One agent should be given instead of the other in certain situations.
2. Both are meant to be given together.
3. One was meant to replace the other, but the old one was never stopped.

Using more than one medicine on purpose for the same problem is called multimodal therapy. The Joint Commission says pain medicines and nausea medicines are common examples, and blood pressure medicines and anticoagulants also appear.

Worked example: two blood pressure orders

A patient's profile shows lisinopril for high blood pressure. A new prescription arrives for enalapril, also for high blood pressure. MedlinePlus lists enalapril as another ACE inhibitor (angiotensin-converting enzyme inhibitor), the same medicine class as lisinopril.

• What you recognize: Two medicines, same indication, same class. This is a therapeutic duplication flag.
• What you cannot tell: whether the prescriber meant to switch the patient and the lisinopril was never stopped, or whether something else was intended.
• What you do: Bring it to the pharmacist, noting both prescribers, the order dates and anything the patient says, such as "My doctor changed my pill." The pharmacist clarifies the prescriber's intent.

Changed case: same purpose, likely planned

Suppose instead the new medicine is a different kind of blood pressure medicine, and the patient says the doctor is "adding one." MedlinePlus says lisinopril is used alone or with other medicines for high blood pressure, so combining medicines can be intended.

It is still a therapeutic duplication by definition, because the purpose is the same. What changed is the likely explanation, not the label. The pharmacist still confirms it.

Shared purpose does not allow a swap

Suppose a patient asks, "Both are for blood pressure, so can you just give me the other one?" A shared indication does not make two medicines interchangeable. The PTCE content outline lists therapeutic substitution among the issues that require a pharmacist. Route the question; don't swap.

Whose rule is this? The Joint Commission's expectations are accreditation standards for the organizations it accredits. They are not a federal law that applies to every pharmacy. Your workplace procedures and your state's rules determine exactly how you route a flag.

Question 2

A patient is due to pick up two new prescriptions for nausea from the same prescriber. The directions don't say whether to take them together or one instead of the other. Is this a duplicate ingredient, a therapeutic duplication or neither? What is the missing fact?

Interactions: One Thing Changes Another

Plain-English takeaway: An interaction happens when something else, such as another drug, a food or a health condition, changes what a medicine does. The FDA says interactions can make a drug less effective, cause unexpected side effects, or increase a drug's action.

An interaction always involves two things. It is not a property of one medicine alone. The PTCE content outline names several pairings:

• Drug–drug: The FDA gives the example of a sleep medicine (a sedative) plus an allergy medicine (an antihistamine). Together they can slow reactions and make driving dangerous.
• Drug–dietary supplement: MedlinePlus lists ginkgo, garlic, ginseng, St. John's wort and other products that may interact with warfarin.
• Drug–nutrient or food: MedlinePlus says vitamin K–containing foods can affect how warfarin works. It advises eating consistent amounts from week to week.
• Drug–disease (drug–condition): The FDA says someone with high blood pressure could have an unwanted reaction to a nasal decongestant.
• Drug–laboratory: A substance changes a test result rather than the body's response. The FDA warns that biotin, often found in dietary supplements, can interfere with certain lab tests. The incorrect results may go undetected. The FDA has received reports of falsely low troponin results, troponin being a blood test related to the heart.

Evidence skill: "may interact" does not say which way

A reference that lists a possible interaction is not the same as a reference that tells you its direction. Direction means whether the effect gets stronger or weaker, and by how much. Report what the source says, and add nothing.

Compare these three MedlinePlus statements about warfarin:

• Garlic, ginkgo and others "may interact." The source says an interaction is possible but does not say which way for each product.
• Some medicines, vitamins, supplements and herbal products "may increase the risk for bleeding." Here the direction is stated, but only as a group statement. It does not tell you which listed product does it.
• Cigarette smoking "may decrease the effectiveness." The direction is stated for that exposure.

For lisinopril, MedlinePlus lists aspirin, NSAIDs (nonsteroidal anti-inflammatory drugs) such as ibuprofen and naproxen, and potassium supplements as products that may interact. It does not describe what happens. Your accurate handoff is "the reference lists this as a possible interaction," not a prediction of the result.

Question 3

A customer taking lisinopril asks you, "Will this potassium supplement make my blood pressure medicine stronger?" Based only on the MedlinePlus source, what can you accurately say, and what should you do?

Contraindication vs. General Caution

Plain-English takeaway: A contraindication says don't use this medicine in this situation: for this patient or circumstance, the risk is judged too high for any benefit to justify. A caution says use may be possible, but it needs care. That care might be monitoring, a dose change, avoiding a particular combination, or checking with a professional first.

The federal labeling regulation for prescription drug prescribing information, 21 CFR 201.57, puts these in separate sections:

• Contraindications: situations where the drug should not be used because the risk clearly outweighs any possible benefit. The situation can depend on a patient's age, sex, other therapy, disease state or other condition. Only known hazards belong there, not theoretical ones. If none are known, the section must say "None."
• Warnings and precautions: clinically significant risks, including risks from drug–drug interactions. This section also covers limits such as avoiding certain combinations and steps to take if a problem occurs, such as changing the dose.

Two consequences follow:

• A contraindication applies to a situation. It does not mean "never for anyone."
• A caution is not "minor." It means the risk is managed rather than ruled out.

Seeing the difference on one OTC label

Fictional label, written for this lesson. DrugX and DrugY are not real medicines, and these statements are not instructions for any real product.

Suppose one OTC product's Warnings section contains these two statements:

• "Do not use" if you are taking DrugX. This is do-not-use wording.
• "Ask a doctor or pharmacist before use" if you are taking DrugY. Use is not ruled out, but someone must check first.

The point is to recognize the two levels of wording, not to memorize any product's rules. The FDA notes that a real OTC label's Warnings section tells you when to talk to a doctor or pharmacist, which conditions may make the drug unsafe, when not to use it, and when to stop. Always read the actual label in front of you.

A prescription example, and an evidence limit

MedlinePlus tells patients: "Do not take lisinopril if you are pregnant," because it may harm the fetus. That is do-not-use wording. MedlinePlus also says some other medicines "may cause dosing changes or extra monitoring" with lisinopril, which is caution-level wording.

MedlinePlus is a patient summary, not the official prescribing information. To learn whether a situation appears in a specific product's formal Contraindications section, the pharmacist checks that product's labeling. Strong wording in a patient leaflet is evidence of seriousness. It does not tell you which official label section the situation sits in.

Changed case: timing can matter

MedlinePlus says to tell the doctor or pharmacist if a patient takes valsartan and sacubitril (listed under the brand Entresto), or has stopped it within the last 36 hours. It says the doctor will probably tell the patient not to take lisinopril in that case.

Two patients can share the same medicine history and differ only in when they took the last dose. The stop date is therefore a fact the pharmacist needs. Collect it; don't judge it.

Symptoms are facts, not proof of cause

Suppose a patient reports a new symptom after starting a combination. That timing alone does not prove the medicine caused it. You still report it. The same federal regulation says a label warning should be added once there is reasonable evidence of a causal link, without waiting for definite proof. Reporting a symptom is not a claim about its cause.

Question 4

Two label statements appear for one fictional OTC product: "Do not use if you are taking DrugX" and "Ask a doctor or pharmacist before use if you are taking DrugY." A customer takes DrugY. A coworker says, "It only says ask, so it's fine." What's wrong with that reasoning?

What the Pharmacist Needs for a Flagged Combination

Plain-English takeaway: A flag tells you something might be wrong. The pharmacist needs specific facts to decide what, if anything, to do. Your handoff should hold those facts, written without your own guesses.

The PTCE content outline lists drug utilization review (checking a prescription against the patient's other medicines, conditions and allergies), drug interactions, allergies, adverse drug events, OTC recommendations and therapeutic substitution among the issues that require a pharmacist. Your workplace procedures and state rules set exactly what you may do. The clinical decision is not yours.

Facts the sources show can change the review:

1. Exact products and active ingredients, with amounts, strength and dosage form. This includes combination products.
2. Everything the patient uses: prescription, OTC, vitamins, minerals, supplements and herbal products. The FDA tells patients to share all of these.
3. Recent changes: what was started, stopped or replaced, and when. The 36-hour lisinopril example shows why timing matters.
4. Who prescribed what, and whether a new order is meant to add a medicine or replace one. The FDA notes added risk when people see more than one doctor.
5. Relevant conditions and patient factors, such as pregnancy, diabetes, kidney or heart disease, past angioedema (serious swelling) or allergies. These are the kinds of factors MedlinePlus says to report.
6. Diet and other exposures, such as changes in vitamin K–containing foods, potassium-containing salt substitutes, alcohol and tobacco.
7. Upcoming lab tests or procedures, such as biotin use before lab testing, or surgery or dental work for a patient on warfarin or lisinopril.
8. Anything the patient reports feeling, in their own words.

Worked example: building a handoff

A customer with warfarin on their profile is buying ibuprofen and a ginkgo supplement. They mention dental work next week. They also started a new prescription from a second doctor last month. Following your workplace procedure, you ask whether they have noticed any unusual bleeding or bruising, and they answer, "No, nothing like that."

Your note to the pharmacist:

"Patient on warfarin is purchasing ibuprofen (OTC) and ginkgo. Both are listed in our reference as possible warfarin interactions. Dental procedure next week. New prescription from a second prescriber last month. When asked about unusual bleeding or bruising, patient said, 'No, nothing like that.'"

Notice what the note leaves out. It doesn't say "this will cause bleeding," because the reference does not state a direction for each item. It doesn't say "it's probably fine." It states facts and where they came from.

Notice also how the symptom line is written. It records the question that was actually asked and the patient's actual answer. If you had not asked, the note would say nothing about symptoms. Never write a negative finding, such as "no symptoms," that nobody checked.

Changed case: a reported symptom

Same customer, but when you ask, they say, "My nose has been bleeding a lot and won't stop." This is no longer a routine queue item. Get the pharmacist now, and follow your workplace's emergency procedure if the patient seems to be in danger.

The reverse also holds. A patient who reports none of the symptoms on a reference list has not been shown to be safe. Published symptom lists are examples, not complete rules for deciding how urgent something is. Any concern goes to the pharmacist.

Question 5

A pharmacist asks you to gather facts about a flag between a patient's lisinopril and a new OTC purchase. Which of these should you collect: (a) the product's active ingredients and amounts, (b) whether the patient has diabetes or kidney disease, (c) your opinion of whether the combination is safe, (d) other supplements the patient uses?

Independent Practice

Question 6

A profile shows plain lisinopril. A new prescription arrives for a product that MedlinePlus lists as containing lisinopril and hydrochlorothiazide. The names look completely different. Which question does this raise, and why might it be missed?

Question 7

A customer buying an OTC acid reducer containing cimetidine says they take warfarin. The FDA's example label wording says: for products containing cimetidine, ask a doctor or pharmacist before use if taking theophylline, warfarin or phenytoin. Is this a contraindication-level statement or a caution? What do you do?

Question 8

A patient taking warfarin says they've decided to "eat a big salad every day now" instead of their usual diet. Which interaction category is this, what does the source support saying, and what does it not support?

Question 9

A patient mentions they take a biotin supplement and have blood work scheduled tomorrow. No medicine-to-medicine conflict appears on screen. Is there anything to flag?

Question 10

Two medicines are both prescribed for pain by the same prescriber. A coworker says, "Same purpose means one of them is an error. Cancel the newer one." What's wrong, and what's the correct next step?

Question 11

A patient who stopped a medicine "a few days ago" is now picking up a new prescription that a reference says should not be combined with it within a specific time window. The patient seems sure of the timing. Which fact do you record, and why not decide yourself?

Key Points to Remember

• Duplicate ingredient: the same active ingredient from more than one product. Read the ingredient list, not the names, and remember that combination products hide duplicates.
• Therapeutic duplication: more than one medicine for the same purpose. It may be an error or intended; the pharmacist clarifies the prescriber's intent. A shared purpose does not authorize a swap.
• Interaction: something else changes a medicine's action or its test results. It can be a drug, supplement, food or nutrient, condition or lab test. "May interact" is not a statement of direction.
• Contraindication vs. caution: do-not-use in a specific situation versus use with care, checking or monitoring. A caution is not permission, and a patient leaflet's strong wording does not tell you the official label section.
• For a flagged combination, gather exact ingredients and amounts, the full product list, recent changes with dates, prescribers and intent, relevant conditions, diet and exposures, upcoming tests or procedures, and reported symptoms. Hand off facts without adding guesses, record only what was actually asked and answered, and escalate symptoms immediately.
• Correct arithmetic, a shared purpose or a short symptom list never replaces the pharmacist's review.

Review: Connect the mechanism to the concern

• Interactions: One Thing Changes Another
• Contraindication vs. General Caution